Alpna joined Nura Bio as Chief Executive Officer, President and Board Member in August 2019. As a seasoned executive and entrepreneur, she brings over 25 years of diverse biotech industry experience leading drug-development, commercialization and business creation. Prior to joining Nura Bio, Alpna was Chief Operating Officer of Vir Biotechnology. Alpna served at Biogen for two decades in senior executive roles based in the United States, Europe and Asia. Most recently she was Senior Vice President and Global Head of Biogen’s Biosimilars Business Unit, where she led the creation and launch of the business with nearly $400 million in annual revenues. Earlier, as Program Executive of Tecfidera – Biogen’s first oral multiple sclerosis drug – she successfully led the product franchise from pivotal trials to regulatory approvals and blockbuster commercial launches worldwide. Alpna was also the founding Managing Director of Biogen Idec India and was a member of the Asia Pac senior leadership team. She holds a PhD in Biochemistry and Molecular Biology from the University of Massachusetts Medical School and conducted her postdoctoral research in Immunology and Structural Biology at Harvard University, both as a Fellow of the Howard Hughes Medical Institute. Alpna is a graduate of Harvard Business School’s Advanced Management Program. In addition to Nura Bio, she serves on the boards of Seagen (NASDAQ: SGEN) and Bio Techne (NASDAQ: TECH).